Abstract 2792
Background
Patient education is quite a current notion that has proved its efficiency. It has been shown as discussed in previous sections that it improves quite significantly treatment outcomes. Through education and support programs, patients health literacy is improved and so is the adherence of treatment. In this light, an education and support program was adapted at the Mohamed VI center for cancer treatment in Casablanca, with the following objectives: 1. Improve patient’s adherence to treatment 2. Increase early detection of chemotherapy side effects between cures 3. Improve quality of life and avoid toxic deaths.
Methods
In total, 96 patients were included into the program for a period of one year (February 2017- February 2018) and their satisfaction evaluated.
Results
In total, 96 patients were included into the program for a period of one year (February 2017- February 2018) and their satisfaction evaluated. 86,5% of the respondents were female while 13,5% were male. Of this, 70,8 % were literate while 29,2% were illetrate. Most of them, 57,2% had some awareness about cancer before they were included into the program while the rest , 42,8% had no cancer awareness. Most of the patients, 86,5% found that the videos and flyers were easy to understand while 80,2% reported that the same was helpful. 76% of the respondents admitted that the program had helped them become more proactive in their treatment. 78,1% of them were satisfied with the mobile phone calls in managing their complications at home without necessaroly coming to the hospital. 99% of the patients said that they would likely recommend the program to other patients. In overall, 87,5% of the patients were satisfied with the education program while only 3,1 % were dissatisfied. The rest of the respondents, 9,3% were neither satisfied nor dissatisfied.
Conclusions
At the end of the study, our findings were generally comparable to those in the literature and all the indicators were achieved. Therefore, this pilot program should be fully implemented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract